Key result
New oral anticoagulants, specifically dabigatran, rivaroxaban, and apixaban, require specific practical management strategies for monitoring, reversal, and peri-procedural use.
Design
Review
Authors
Loading...
Highlights need for NOAC-specific protocols in practice; leaves open standardization pending prospective validation.
This review summarizes clinical trial results and practical management aspects, such as monitoring, reversal, and peri-procedural use, for new oral anticoagulants including dabigatran, rivaroxaban, and apixaban.
Thomas G. DeLoughery (2011) studied this question. New oral anticoagulants, specifically dabigatran, rivaroxaban, and apixaban, require specific practical management strategies for monitoring, reversal, and peri-procedural use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: